IDYA Logo

IDEAYA Biosciences, Inc. (IDYA) 

NASDAQ
Market Cap
$2.3B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
565 of 774
Rank in Industry
304 of 432

Largest Insider Buys in Sector

IDYA Stock Price History Chart

IDYA Stock Performance

About IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers …

Insider Activity of IDEAYA Biosciences, Inc.

Over the last 12 months, insiders at IDEAYA Biosciences, Inc. have bought $0 and sold $19.26M worth of IDEAYA Biosciences, Inc. stock.

On average, over the past 5 years, insiders at IDEAYA Biosciences, Inc. have bought $3.45M and sold $11.67M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,062 shares for transaction amount of $67,408 was made by BVF PARTNERS L P/IL (10 percent owner) on 2020‑06‑30.

List of Insider Buy and Sell Transactions, IDEAYA Biosciences, Inc.

2024-05-29SaleChief Scientific Officer
28,500
0.038%
$36.24$1.03M+1.81%
2024-05-16SalePresident and CEO
34,433
0.0453%
$41.81$1.44M-10.93%
2024-05-15SalePresident and CEO
83,856
0.112%
$42.90$3.6M-12.90%
2024-05-14SalePresident and CEO
56,711
0.0746%
$41.61$2.36M-11.49%
2024-02-09SalePresident and CEO
23,557
0.0351%
$45.54$1.07M-13.89%
2024-02-09SaleSee Remarks
2,000
0.003%
$46.02$92,045-13.89%
2024-02-08SalePresident and CEO
75,815
0.1121%
$45.15$3.42M-11.76%
2024-02-01SalePresident and CEO
628
0.0009%
$45.00$28,260-10.93%
2024-01-22SaleSee Remarks
2,000
0.0028%
$42.03$84,050-6.71%
2024-01-16SalePresident and CEO
62,739
0.0965%
$40.17$2.52M-0.75%
2024-01-12SalePresident and CEO
12,261
0.0191%
$40.04$490,913+0.80%
2024-01-12SaleSee Remarks
2,000
0.003%
$38.01$76,026+0.80%
2023-12-15SalePresident and CEO
75,000
0.1165%
$35.03$2.63M+12.76%
2023-12-15SaleChief Legal Officer
10,000
0.0155%
$35.04$350,371+12.76%
2023-12-14SaleSee Remarks
2,000
0.0031%
$34.00$68,002+16.39%
2023-11-03SaleChief Legal Officer
5,163
0.0085%
$30.09$155,360+34.29%
2023-09-12SaleChief Legal Officer
1,000
0.0018%
$30.00$30,005+30.51%
2023-09-05SaleChief Legal Officer
1,737
0.0031%
$30.03$52,160+33.04%
2023-09-01SaleSee Remarks
2,000
0.0035%
$30.01$60,016+28.75%
2023-09-01SaleChief Legal Officer
2,100
0.0037%
$30.03$63,063+28.75%

Insider Historical Profitability

<0.0001%
DIEKMAN JOHN Ddirector
2844545
3.2911%
$26.6310<0.0001%
SHANNON TIMOTHY Mdirector
2660713
3.0784%
$26.6310<0.0001%
CANAAN X L.P.10 percent owner
2660713
3.0784%
$26.6310<0.0001%
Alexandria Venture Investments, LLC10 percent owner
432384
0.5003%
$26.6310<0.0001%
BVF PARTNERS L P/IL
233150
0.2698%
$26.6331<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$445.61M12.2210.16M+1,043.34%+$406.64M0.03
BlackRock$261.76M7.185.97M+9.73%+$23.2M0.01
Federated Hermes$213.08M5.844.86M+25.04%+$42.66M0.49
The Vanguard Group$182.35M54.16M+19.56%+$29.84M<0.01
T. Rowe Price$177.82M4.884.05M+13.63%+$21.34M0.02
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.